Tennessee Bill Threatens CVS Pharmacy Closures, Sparks PBM Debate
A proposal in the Tennessee legislature could force CVS Health to significantly alter its business model or exit the state entirely, becoming a key test case for regulating pharmacy benefit managers (PBMs) nationwide. The bill, HB1959, aims to address conflicts of interest by prohibiting a single company from owning both a retail pharmacy and a pharmacy benefit manager.
Understanding Pharmacy Benefit Managers
Pharmacy benefit managers (PBMs) play a crucial role in the prescription drug market, negotiating drug prices, processing pharmacy claims, and managing drug benefits for health insurers, and employers. CVS Health uniquely operates as a retail pharmacy (approximately 9,000 locations across the US), a health insurer (Aetna), and a PBM (CVS Caremark).
The Core of the Tennessee Bill
The proposed legislation would prevent companies like CVS Health from simultaneously owning a retail pharmacy and a PBM. If enacted, CVS Health has stated it may be forced to close all 134 of its pharmacies in Tennessee, potentially impacting over 2,000 jobs. CVS Health argues that separating these entities is not feasible, citing a lack of potential buyers for its Tennessee pharmacies.
Concerns Over Conflicts of Interest
Proponents of the bill, including Tennessee State Senator Bobby Harshbarger, a pharmacist and Republican, argue that the current structure creates a “structural conflict in the pharmacy marketplace.” Senator Harshbarger believes separating PBMs from pharmacies will address this conflict and improve market fairness.
A 2024 audit by the Tennessee Department of Commerce and Insurance revealed that CVS Caremark was underpaying independent pharmacies while reimbursing its own CVS pharmacies at significantly higher rates—in some cases, up to 16,000% higher—for the same medications. This audit fueled concerns about anti-competitive practices.
CVS Response and Opposition
CVS Health contends that the bill will harm patients and limit access to care. The company has launched a seven-figure advertising campaign warning of potential store closures and job losses. Amy Thibault, a CVS spokesperson, stated the bill is “bad for Tennessee” and its patients. CVS as well points to its role in acquiring and operating Rite Aid stores following Rite Aid’s bankruptcy as evidence of its commitment to maintaining pharmacy access.
Broader Implications and National Trends
Tennessee is not alone in considering such legislation. Arkansas passed a law in 2024 prohibiting PBMs from owning pharmacies, though its implementation is currently stayed due to a lawsuit filed by CVS. Similar legislative efforts are underway in New York, Vermont, Texas, and Indiana. Nationally, there’s growing scrutiny of PBMs, with the Federal Trade Commission (FTC) releasing a report in January finding that the “big three” PBMs—CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx—control roughly 60% of the market and have generated billions in revenue by increasing drug costs. The FTC report highlighted concerns about inflated drug prices for conditions like heart disease and cancer.
Legal Challenges and Ongoing Debate
The debate over PBM regulation is complex. Some legal experts argue that the integration of PBMs and pharmacies restricts price competition and harms consumers. However, industry groups like the Pharmaceutical Care Management Association maintain that such policies could negatively impact patient health and increase drug costs. A study funded by the Pharmaceutical Care Management Association, conducted by economics professor Moiz Bhai, suggests that bills like the one in Tennessee could lead to pharmacy closures, increased drug costs, and more hospitalizations.
The outcome of the Tennessee bill could set a precedent for similar legislation across the country, potentially reshaping the pharmaceutical landscape and impacting access to prescription drugs for millions of Americans.
Worth a look